Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBIT: 2016-2025

Historic EBIT for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$27.4 million.

  • UroGen Pharma's EBIT fell 56.09% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$133.4 million, marking a year-over-year decrease of 59.32%. This contributed to the annual value of -$96.8 million for FY2024, which is 47.68% down from last year.
  • Per UroGen Pharma's latest filing, its EBIT stood at -$27.4 million for Q3 2025, which was up 33.93% from -$41.4 million recorded in Q2 2025.
  • UroGen Pharma's 5-year EBIT high stood at -$13.5 million for Q3 2023, and its period low was -$41.4 million during Q2 2025.
  • Moreover, its 3-year median value for EBIT was -$25.7 million (2024), whereas its average is -$24.4 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 40.81% in 2021, then crashed by 89.32% in 2024.
  • Over the past 5 years, UroGen Pharma's EBIT (Quarterly) stood at -$19.9 million in 2021, then decreased by 1.84% to -$20.3 million in 2022, then climbed by 27.97% to -$14.6 million in 2023, then crashed by 89.32% to -$27.7 million in 2024, then plummeted by 56.09% to -$27.4 million in 2025.
  • Its EBIT stands at -$27.4 million for Q3 2025, versus -$41.4 million for Q2 2025 and -$36.9 million for Q1 2025.